{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:20:09Z","timestamp":1789708809294,"version":"4.0.1"},"reference-count":71,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI105813"],"award-info":[{"award-number":["AI105813"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI161400"],"award-info":[{"award-number":["AI161400"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI173816"],"award-info":[{"award-number":["AI173816"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["RP210126"],"award-info":[{"award-number":["RP210126"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1S10OD030432"],"award-info":[{"award-number":["1S10OD030432"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA054174"],"award-info":[{"award-number":["P30CA054174"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP210105"],"award-info":[{"award-number":["RP210105"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP220470"],"award-info":[{"award-number":["RP220470"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022750","name":"Office of the Vice President for Research, University of Minnesota","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022750","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021533","name":"Morrison Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021533","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["WI215053"],"award-info":[{"award-number":["WI215053"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["AI135574"],"award-info":[{"award-number":["AI135574"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["AI167416"],"award-info":[{"award-number":["AI167416"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mucosalimmunology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mucosal Immunology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.mucimm.2025.06.010","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T12:30:06Z","timestamp":1751545806000},"page":"1098-1112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tofacitinib ameliorates Campylobacter-induced intestinal pathology by suppressing IFN\u03b3 producing ILCs and T cells"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6177-2379","authenticated-orcid":false,"given":"Anna A.","family":"Korchagina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey A.","family":"Shein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne T.","family":"Muraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0448-7016","authenticated-orcid":false,"given":"Justin","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6947-4447","authenticated-orcid":false,"given":"Qiangxing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8236-0058","authenticated-orcid":false,"given":"Anna A.","family":"Tumanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6115-4770","authenticated-orcid":false,"given":"Austin W.","family":"Todd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9052-557X","authenticated-orcid":false,"given":"Carlos E.","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Tamayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8982-5177","authenticated-orcid":false,"given":"Paolo","family":"Casali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1857-9199","authenticated-orcid":false,"given":"Ekaterina","family":"Koroleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6042-0152","authenticated-orcid":false,"given":"Alexei V.","family":"Tumanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.mucimm.2025.06.010_b0005","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrd.2017.267","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.mucimm.2025.06.010_b0010","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.mucimm.2025.06.010_b0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-9255-7-41","article-title":"Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis","volume":"7","author":"Meyer","year":"2010","journal-title":"J Inflamm"},{"issue":"3","key":"10.1016\/j.mucimm.2025.06.010_b0020","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/ecco-jcc\/jjac141","article-title":"Tofacitinib for the treatment of ulcerative colitis: an integrated summary of up to 7.8 years of safety data from the global clinical programme","volume":"17","author":"Sandborn","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.mucimm.2025.06.010_b0025","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-024-01008-6","article-title":"Strategies for targeting cytokines in inflammatory bowel disease","author":"Neurath","year":"2024","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.mucimm.2025.06.010_b0030","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/infdis\/jiac040","article-title":"Tofacitinib treatment in primary herpes simplex encephalitis interferes with antiviral response","volume":"225","author":"Krzyzowska","year":"2022","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.mucimm.2025.06.010_b0035","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13075-021-02509-8","article-title":"Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation","volume":"23","author":"Hawerkamp","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.mucimm.2025.06.010_b0040","doi-asserted-by":"crossref","unstructured":"Tack DM, Ray L, Griffin PM, Cieslak PR, Dunn J, Rissman T et al. Preliminary Incidence and Trends of Infections with Pathogens Transmitted Commonly Through Food - Foodborne Diseases Active Surveillance Network, 10 U.S. Sites, 2016-2019. MMWR Morb Mortal Wkly Rep 2020; 69(17): 509-514.","DOI":"10.15585\/mmwr.mm6917a1"},{"issue":"3","key":"10.1016\/j.mucimm.2025.06.010_b0045","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1128\/CMR.00006-15","article-title":"Global epidemiology of campylobacter infection","volume":"28","author":"Kaakoush","year":"2015","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"10.1016\/j.mucimm.2025.06.010_b0050","first-page":"287","article-title":"Risk factors and clinical implication of superimposed Campylobacter jejuni infection in patients with underlying ulcerative colitis","volume":"4","author":"Arora","year":"2016","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"8","key":"10.1016\/j.mucimm.2025.06.010_b0055","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1097\/MIB.0000000000000468","article-title":"A multihit model: colitis lessons from the interleukin-10-deficient mouse","volume":"21","author":"Keubler","year":"2015","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"10.1016\/j.mucimm.2025.06.010_b0060","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1128\/IAI.00833-06","article-title":"C57BL\/6 and congenic interleukin-10-deficient mice can serve as models of Campylobacter jejuni colonization and enteritis","volume":"75","author":"Mansfield","year":"2007","journal-title":"Infect Immun"},{"issue":"4","key":"10.1016\/j.mucimm.2025.06.010_b0065","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/mi.2013.97","article-title":"Contrasting immune responses mediate Campylobacter jejuni-induced colitis and autoimmunity","volume":"7","author":"Malik","year":"2014","journal-title":"Mucosal Immunol"},{"issue":"3","key":"10.1016\/j.mucimm.2025.06.010_b0070","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41385-020-00353-8","article-title":"Campylobacter infection promotes IFNgamma-dependent intestinal pathology via ILC3 to ILC1 conversion","volume":"14","author":"Muraoka","year":"2021","journal-title":"Mucosal Immunol"},{"issue":"2","key":"10.1016\/j.mucimm.2025.06.010_b0075","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/mi.2017.66","article-title":"Campylobacter jejuni impairs sodium transport and epithelial barrier function via cytokine release in human colon","volume":"11","author":"B\u00fccker","year":"2018","journal-title":"Mucosal Immunol"},{"issue":"5","key":"10.1016\/j.mucimm.2025.06.010_b0080","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.mucimm.2025.06.010_b0085","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/mi.2017.38","article-title":"Jak3 deficiency blocks innate lymphoid cell development","volume":"11","author":"Robinette","year":"2018","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.mucimm.2025.06.010_b0090","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.3389\/fimmu.2019.02972","article-title":"JAK inhibition differentially affects NK cell and ILC1 homeostasis","volume":"10","author":"Vian","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.mucimm.2025.06.010_b0095","article-title":"IL-23 contributes to campylobacter jejuni-induced intestinal pathology via promoting IL-17 and IFNgamma responses by innate lymphoid cells","volume":"11","author":"Jing","year":"2020","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.mucimm.2025.06.010_b0100","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1172\/JCI26705","article-title":"MUC1 cell surface mucin is a critical element of the mucosal barrier to infection","volume":"117","author":"McAuley","year":"2007","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.mucimm.2025.06.010_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19490976.2020.1814121","article-title":"A porcine ligated loop model reveals new insight into the host immune response against Campylobacter jejuni","volume":"12","author":"Negretti","year":"2020","journal-title":"Gut Microbes"},{"issue":"1","key":"10.1016\/j.mucimm.2025.06.010_b0110","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2022.2038854","article-title":"Flagellum and toxin phase variation impacts intestinal colonization and disease development in a mouse model of Clostridioides difficile infection","volume":"14","author":"Trzilova","year":"2022","journal-title":"Gut Microbes"},{"issue":"3","key":"10.1016\/j.mucimm.2025.06.010_b0115","doi-asserted-by":"crossref","first-page":"G155","DOI":"10.1152\/ajpgi.00311.2015","article-title":"JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines","volume":"310","author":"Danese","year":"2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"7","key":"10.1016\/j.mucimm.2025.06.010_b0120","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1084\/jem.20082683","article-title":"STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing","volume":"206","author":"Pickert","year":"2009","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.mucimm.2025.06.010_b0125","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1128\/IAI.74.5.2697-2705.2006","article-title":"Campylobacter jejuni induces maturation and cytokine production in human dendritic cells","volume":"74","author":"Hu","year":"2006","journal-title":"Infect Immun"},{"issue":"11","key":"10.1016\/j.mucimm.2025.06.010_b0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015398","article-title":"Delineation of the innate and adaptive T-cell immune outcome in the human host in response to Campylobacter jejuni infection","volume":"5","author":"Edwards","year":"2010","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.mucimm.2025.06.010_b0135","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1128\/IAI.71.5.2626-2633.2003","article-title":"Induction of proinflammatory responses in the human monocytic cell line THP-1 by Campylobacter jejuni","volume":"71","author":"Jones","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.mucimm.2025.06.010_b0140","doi-asserted-by":"crossref","first-page":"8010","DOI":"10.1038\/ncomms9010","article-title":"Intestinal macrophages arising from CCR2(+) monocytes control pathogen infection by activating innate lymphoid cells","volume":"6","author":"Seo","year":"2015","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.mucimm.2025.06.010_b0145","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1002\/eji.201242847","article-title":"CD64 distinguishes macrophages from dendritic cells in the gut and reveals the Th1-inducing role of mesenteric lymph node macrophages during colitis","volume":"42","author":"Tamoutounour","year":"2012","journal-title":"Eur J Immunol"},{"issue":"1","key":"10.1016\/j.mucimm.2025.06.010_b0150","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1365-2249.2009.03933.x","article-title":"Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex","volume":"157","author":"King","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.mucimm.2025.06.010_b0155","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.784947","article-title":"Humanized mice as a valuable pre-clinical model for cancer immunotherapy research","volume":"11","author":"Cogels","year":"2021","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.mucimm.2025.06.010_b0160","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/s41590-024-01880-3","article-title":"A humanized mouse that mounts mature class-switched, hypermutated and neutralizing antibody responses","volume":"25","author":"Chupp","year":"2024","journal-title":"Nat Immunol"},{"issue":"11","key":"10.1016\/j.mucimm.2025.06.010_b0165","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.4049\/jimmunol.1502673","article-title":"Phenotypic and functional plasticity of murine intestinal NKp46+ Group 3 innate lymphoid cells","volume":"196","author":"Verrier","year":"2016","journal-title":"J Immunol"},{"issue":"7436","key":"10.1016\/j.mucimm.2025.06.010_b0170","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nature11813","article-title":"A T-bet gradient controls the fate and function of CCR6-RORgammat+ innate lymphoid cells","volume":"494","author":"Klose","year":"2013","journal-title":"Nature"},{"issue":"45","key":"10.1016\/j.mucimm.2025.06.010_b0175","doi-asserted-by":"crossref","first-page":"18324","DOI":"10.1073\/pnas.1112064108","article-title":"Fate mapping analysis of lymphoid cells expressing the NKp46 cell surface receptor","volume":"108","author":"Narni-Mancinelli","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.mucimm.2025.06.010_b0180","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-213X-1-4","article-title":"Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus","volume":"1","author":"Srinivas","year":"2001","journal-title":"BMC Dev Biol"},{"issue":"9","key":"10.1016\/j.mucimm.2025.06.010_b0185","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41577-020-0282-9","article-title":"Plasticity of innate lymphoid cell subsets","volume":"20","author":"Bal","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.mucimm.2025.06.010_b0190","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1146077","article-title":"Transcriptional control of ILC identity","volume":"14","author":"Korchagina","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.mucimm.2025.06.010_b0195","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/ni1022","article-title":"An essential function for the nuclear receptor RORgamma(t) in the generation of fetal lymphoid tissue inducer cells","volume":"5","author":"Eberl","year":"2004","journal-title":"Nat Immunol"},{"issue":"6371","key":"10.1016\/j.mucimm.2025.06.010_b0200","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1126\/science.aam5809","article-title":"S1P-dependent interorgan trafficking of group 2 innate lymphoid cells supports host defense","volume":"359","author":"Huang","year":"2018","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.mucimm.2025.06.010_b0205","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1128\/IAI.00958-06","article-title":"Disruption of tight junctions and induction of proinflammatory cytokine responses in colonic epithelial cells by Campylobacter jejuni","volume":"74","author":"Chen","year":"2006","journal-title":"Infect Immun"},{"key":"10.1016\/j.mucimm.2025.06.010_b0210","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2020.590186","article-title":"Campylobacter jejuni serine protease HtrA cleaves the tight junction component claudin-8","volume":"10","author":"Sharafutdinov","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"10.1016\/j.mucimm.2025.06.010_b0215","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ccr.2007.12.020","article-title":"Autocrine IL-6 signaling: a key event in tumorigenesis?","volume":"13","author":"Grivennikov","year":"2008","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.mucimm.2025.06.010_b0220","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1038\/s41467-022-33331-8","article-title":"Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy","volume":"13","author":"Pavlidis","year":"2022","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.mucimm.2025.06.010_b0225","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.stemcr.2024.06.006","article-title":"JAK\/STAT signaling promotes the emergence of unique cell states in ulcerative colitis","volume":"19","author":"Maciag","year":"2024","journal-title":"Stem Cell Rep"},{"issue":"4","key":"10.1016\/j.mucimm.2025.06.010_b0230","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.immuni.2014.09.010","article-title":"Interleukin-22 regulates the complement system to promote resistance against pathobionts after pathogen-induced intestinal damage","volume":"41","author":"Hasegawa","year":"2014","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.mucimm.2025.06.010_b0235","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4049\/jimmunol.1201825","article-title":"Phosphatidylinositol 3-kinase-\u03b3 signaling promotes Campylobacter jejuni-induced colitis through neutrophil recruitment in mice","volume":"190","author":"Sun","year":"2013","journal-title":"J Immunol"},{"issue":"35","key":"10.1016\/j.mucimm.2025.06.010_b0240","doi-asserted-by":"crossref","first-page":"9852","DOI":"10.1073\/pnas.1610253113","article-title":"Network pharmacology of JAK inhibitors","volume":"113","author":"Moodley","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Supplement_2","key":"10.1016\/j.mucimm.2025.06.010_b0245","doi-asserted-by":"crossref","first-page":"S725","DOI":"10.1093\/ecco-jcc\/jjaa014","article-title":"Clinical pharmacology of janus kinase inhibitors in inflammatory bowel disease","volume":"14","author":"Lefevre","year":"2020","journal-title":"J Crohn's Colitis"},{"issue":"4","key":"10.1016\/j.mucimm.2025.06.010_b0250","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1124\/dmd.113.054940","article-title":"The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans","volume":"42","author":"Dowty","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.mucimm.2025.06.010_b0255","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jcmgh.2021.09.004","article-title":"Tofacitinib-induced modulation of intestinal adaptive and innate immunity and factors driving cellular and systemic pharmacokinetics","volume":"13","author":"Texler","year":"2022","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.mucimm.2025.06.010_b0260","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1053\/j.gastro.2011.09.042","article-title":"Campylobacter jejuni induces colitis through activation of mammalian target of rapamycin signaling","volume":"142","author":"Sun","year":"2012","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.mucimm.2025.06.010_b0265","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.chom.2018.07.008","article-title":"LIGHT-HVEM Signaling in Innate Lymphoid Cell Subsets Protects against Enteric Bacterial Infection","volume":"24","author":"Seo","year":"2018","journal-title":"Cell Host Microbe"},{"issue":"10","key":"10.1016\/j.mucimm.2025.06.010_b0270","doi-asserted-by":"crossref","first-page":"6579","DOI":"10.4049\/jimmunol.0901935","article-title":"The natural cytotoxicity receptor NKp46 is dispensable for IL-22-mediated innate intestinal immune defense against Citrobacter rodentium","volume":"183","author":"Satoh-Takayama","year":"2009","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.mucimm.2025.06.010_b0275","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.immuni.2020.12.004","article-title":"Group 1 innate lymphoid-cell-derived interferon-\u03b3 maintains anti-viral vigilance in the mucosal epithelium","volume":"54","author":"Shannon","year":"2021","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.mucimm.2025.06.010_b0280","doi-asserted-by":"crossref","first-page":"567","DOI":"10.4049\/jimmunol.172.1.567","article-title":"Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages","volume":"172","author":"Williams","year":"2004","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.mucimm.2025.06.010_b0285","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/ibd\/izz213","article-title":"Tofacitinib reprograms human monocytes of IBD patients and healthy controls toward a more regulatory phenotype","volume":"26","author":"Cordes","year":"2020","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"10.1016\/j.mucimm.2025.06.010_b0290","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/ibd\/izy364","article-title":"A JAK1 selective kinase inhibitor and tofacitinib affect macrophage activation and function","volume":"25","author":"De Vries","year":"2019","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.mucimm.2025.06.010_b0295","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.4049\/jimmunol.1200310","article-title":"Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedback","volume":"189","author":"Pattison","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.mucimm.2025.06.010_b0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111563","article-title":"Regulation of IL-10 expression and function by JAK-STAT in CD8(+) T cells","volume":"128","author":"Pei","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.mucimm.2025.06.010_b0305","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/exd.14059","article-title":"The janus kinase inhibitor tofacitinib impacts human dendritic cell differentiation and favours M1 macrophage development","volume":"29","author":"Stalder","year":"2020","journal-title":"Exp Dermatol"},{"issue":"10","key":"10.1016\/j.mucimm.2025.06.010_b0310","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1086\/644622","article-title":"Campylobacter jejuni strain CG8421: a refined model for the study of Campylobacteriosis and evaluation of Campylobacter vaccines in human subjects","volume":"49","author":"Tribble","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.mucimm.2025.06.010_bib356","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1016\/j.chom.2024.11.006","article-title":"Campylobacter jejuni-derived cytolethal distending toxin promotes colorectal cancer metastasis","volume":"32","author":"He","year":"2024","journal-title":"Cell Host Microbe."},{"issue":"2","key":"10.1016\/j.mucimm.2025.06.010_b0315","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0092-8674(93)80068-P","article-title":"Interleukin-10-deficient mice develop chronic enterocolitis","volume":"75","author":"K\u00fchn","year":"1993","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.mucimm.2025.06.010_b0320","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/ni.1715","article-title":"Cytokine-secreting follicular T cells shape the antibody repertoire","volume":"10","author":"Reinhardt","year":"2009","journal-title":"Nat Immunol"},{"issue":"6401","key":"10.1016\/j.mucimm.2025.06.010_b0325","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/360225a0","article-title":"Mutations in T-cell antigen receptor genes \u03b1 and \u03b2 block thymocyte development at different stages","volume":"360","author":"Mombaerts","year":"1992","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.mucimm.2025.06.010_b0330","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1128\/JB.01252-10","article-title":"Phenotypic and genotypic evidence for L-fucose utilization by Campylobacter jejuni","volume":"193","author":"Muraoka","year":"2011","journal-title":"J Bacteriol"},{"issue":"1","key":"10.1016\/j.mucimm.2025.06.010_b0335","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2297872","article-title":"Hyperbaric oxygen augments susceptibility to C. difficile infection by impairing gut microbiota ability to stimulate the HIF-1\u03b1-IL-22 axis in ILC3","volume":"16","author":"Fachi","year":"2024","journal-title":"Gut Microbes"},{"key":"10.1016\/j.mucimm.2025.06.010_b0340","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jim.2015.02.003","article-title":"Citrobacter rodentium-induced colitis: a robust model to study mucosal immune responses in the gut","volume":"421","author":"Koroleva","year":"2015","journal-title":"J Immunol Methods"},{"issue":"1","key":"10.1016\/j.mucimm.2025.06.010_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2022.101936","article-title":"Dissociation and flow cytometric isolation of murine intestinal epithelial cells for multi-omic profiling","volume":"4","author":"Ge","year":"2023","journal-title":"STAR Protoc"},{"issue":"3","key":"10.1016\/j.mucimm.2025.06.010_b0350","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.immuni.2010.02.011","article-title":"Lymphotoxin beta receptor signaling in intestinal epithelial cells orchestrates innate immune responses against mucosal bacterial infection","volume":"32","author":"Wang","year":"2010","journal-title":"Immunity"}],"container-title":["Mucosal Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933021925000704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933021925000704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:16:42Z","timestamp":1778833002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933021925000704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":71,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1933021925000704"],"URL":"https:\/\/doi.org\/10.1016\/j.mucimm.2025.06.010","relation":{},"ISSN":["1933-0219"],"issn-type":[{"value":"1933-0219","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tofacitinib ameliorates Campylobacter-induced intestinal pathology by suppressing IFN\u03b3 producing ILCs and T cells","name":"articletitle","label":"Article Title"},{"value":"Mucosal Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mucimm.2025.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of Society for Mucosal Immunology.","name":"copyright","label":"Copyright"}]}}